Eugene Lin

This company has deals signed with Amazon, Dell, Fortinet, The government of the United States and the government of Great Britain. Tracey Pretorius is the Senior VP of Cybersecurity for Arqit. She is an 18 year veteran of Microsoft.

I am an ADMA long hauler. It is inevitable that the rapid rise in revenue will translate into improved shareholder value. Almost 100% rise in annual revenue and multiple FDA approvals are bullish indicators.

$ADMA Preliminary Fourth Quarter and Full Year 2021 Revenues and 2022 Strategic Outlook should be available soon.

$ADMA ADMA Biologics should be announcing preliminary fourth quarter and full year 2021 revenues sometime this month. It could be a positive catalyst.

$ADMA has estimated revenue between $20 million and $20.5 million in Q3. Explosive revenue growth.

$ADMA I think Q3 report next month will show at least $20 million in revenue.

$ADMA This stock will reward those with patience. Penny stock company with a high demand product and explosive revenue growth is a setup for a massive short squeeze. Just wait for the catalyst.

$ADMA I have been trading ADMA stock since April 2020 and have made money every trade by buying on the big dips and selling on the spikes. I last sold at $2.60 and bought back at $1.95. Yes I’ve been holding the bag the last few months but ADMA has a history of volatility and the next round of upside volatility is coming. Waiting for a catalyst. This is a good rapidly growing company that sells a product that is in short supply and in high demand. A catalyst will come.

$ADMA We need a blowout 3Q report to get out of the quagmire but I’m patient.

$ADMA
https://www.equities.com/news/adma-adma-gains-1-70-for-september-15